Fenbendazole as a Potential Treatment for Advanced Lymphoma

  • Post comments:0 Comments
📄 7 mins.

Fenbendazole, a broad-spectrum benzimidazole, is commonly used as an anthelmintic drug to treat parasitic infections in animals. It operates by targeting and disrupting tubulin microtubules within the parasites. 

Microtubules are vital for cell division, internal transport, movement, and maintaining cell shape. Consequently, drugs affecting microtubules, like Vinca alkaloids and paclitaxel, have been widely adopted in cancer therapy. Fenbendazole works much like these medications, following a similar approach.

fenbendazole and dca for non hodgkins

This illustration shows α/β heterodimers coming together to create tubulin cylinders, all aligned in the same direction, which gives the microtubule its unique orientation. You can see the microtubule has two different ends that grow at varying speeds. It particularly focuses on the fraying happening at the (+) end, where the dimers start to separate.

Microtubules play a crucial role in how cancer cells divide and multiply, which is why they’re an important focus in stopping the growth of tumors. By focusing on these targets, we have the potential to halt and shrink many types of cancer with fenbendazole.

A notable story is about an 83-year-old man battling stage four lymphoma, who chose not to go through chemotherapy and radiation because of the side effects they bring.  After his own research, he began a daily regimen of 1 gram of fenbendazole, adjusting the dose (1-4 capsules) based on his symptoms.

Six months later, a CT scan revealed a reduction in the size of his mediastinal lymph nodes – the cancerous areas. He then reduced his fenbendazole intake to 1-3 capsules of 222 mg each day. A subsequent PET/CT scan two months later showed further diminishment of the lymphoma tumors.

In a remarkably similar case, reports indicate that a middle-aged man managed to successfully overcome his stage IV Non-Hodgkin lymphoma by using Sodium dichloroacetate (DCA).

What is Non-Hodgkin lymphoma?

Non-Hodgkin lymphoma is a form of cancer that originates in the immune system’s cells, specifically the T or B lymphocytes. It differs histologically from a similar condition, Hodgkin disease, by the absence of Reed-Sternberg cells in biopsy samples. While Hodgkin lymphoma is less common, it is also one of the most treatable cancers, boasting a 5-year survival rate of around 90%.

Typically, one of the first significant indicators of Non-Hodgkin lymphoma is the presence of enlarged, non-painful lymph nodes. Other symptoms of this disease can include fever, unexplained weight loss, fatigue, shortness of breath, night sweats, and cough. The suspicion of this cancer often arises when these symptoms manifest, particularly the painless swelling in lymph nodes, or through the discovery of abnormal results in routine blood tests.

In diagnosing and formulating a treatment plan for Non-Hodgkin lymphoma, computed tomography (CT) scans and biopsies are crucial. These diagnostic tools help confirm the presence of the disease and guide healthcare professionals in choosing the most effective treatment approach for the patient.

Non-Hodgkin Lymphoma is Quite a Common Cancer Diagnosis

non hodgkin lymphoma cancer diagnosis

Non-Hodgkin lymphoma is a relatively common form of cancer, accounting for about 4% of all new cancer diagnoses. Statistically, around 20 out of every 100,000 individuals are diagnosed with this disease each year. In 2014, approximately 660,000 people in the United States were living with Non-Hodgkin lymphoma.

Interestingly, the incidence of new Non-Hodgkin lymphoma cases has been on the rise annually. This increase may be partly attributed to advancements in diagnostic technologies that enable earlier and more accurate detection of such diseases.

how do you get non hodgkin lymphona

Chemotherapy is a standard treatment for many cancers, including Non-Hodgkin lymphoma, and it can be effective in achieving full remission. However, chemotherapy often comes with a range of side effects and potential long-term health implications. Additionally, there is always a risk of cancer relapse, necessitating further rounds of chemotherapy.

These challenges associated with traditional cancer treatments are one reason why some people explore alternative cancer therapies, either independently or with guidance from healthcare professionals.

Sodium dichloroacetate (DCA) is one such alternative treatment option. Originally used for decades to treat congenital mitochondrial diseases in children, DCA’s pharmacokinetics, pharmacodynamics, and side effects were well-understood long before its potential as a cancer treatment was discovered. This accidental finding has sparked interest in DCA as a possible therapy for oncological conditions.

How DCA Works in Fighting Variuos Cancers

Understanding how DCA functions in fighting cancer is crucial. At its core, DCA inhibits a key enzyme crucial for cancer cells: pyruvate dehydrogenase kinase. This inhibition triggers several transformative changes within tumor cells.

Firstly, DCA reduces the Warburg effect, which shifts cellular metabolism back from aerobic glycolysis to normal respiration, thereby decreasing the high acidity inside the cells. Secondly, DCA selectively induces apoptosis in cancer cells, effectively halting tumor growth and reducing their size. Lastly, DCA has the potential to lower the risk of cancer metastasis.

These effects are noteworthy, especially given that the risk of side effects is considerably lower when DCA is used alongside certain dietary supplements. In the event that side effects do occur, they tend to be mild and cause minimal discomfort. These effects are fully reversible and typically resolve within a few days after discontinuing DCA.

DCA presents itself as a promising alternative in cancer treatment, already aiding individuals battling oncological conditions. One particularly remarkable case involves a 52-year-old man who managed to completely resolve his stage IV Non-Hodgkin follicular lymphoma through self-administration of DCA. This case exemplifies the potential of DCA as a viable treatment option for those facing similar diagnoses.

Remarkable Results: Non-Hodgkin’s lymphoma before and after DCA Treatment

dca and non hodgkin lymphoma

A 46 year old man began experiencing worrying symptoms. Over five months, he lost 50 pounds, suffered from persistent fever and intense night sweats. Additionally, he noticed enlarged cervical lymph nodes stretching from the top of his neck to his collarbone.

Concerned, he sought medical attention. A computed tomography (CT) scan revealed pathological lymph nodes in his head, neck, chest, abdomen, and pelvis – a disheartening discovery. Further diagnostic tests, including biopsies from his bone marrow and lymph nodes, confirmed a diagnosis of stage IV Non-Hodgkin follicular lymphoma.

Subsequently, he underwent six cycles of R-CHOP chemotherapy, a regimen including rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. These months of intensive chemotherapy were challenging, but a follow-up CT scan revealed a significant milestone: he was in remission and cancer-free.

Returning to his usual lifestyle, he resumed his everyday activities and maintained regular health check-ups. For a year, he enjoyed good health, a testament to the effectiveness of his treatment and resilience in the face of such a challenging diagnosis.

After a period of remission, the man’s symptoms, including fever, coughing, night sweats, and rapid weight loss of 11 pounds in two weeks, returned. Concerned, he sought medical help again. Unfortunately, diagnostic tests revealed enlarged lymph nodes on the right side of his head and neck – the cancer had relapsed.

Unwilling to endure the harsh side effects of chemotherapy again, particularly the severe nausea and vomiting, he declined conventional treatment. Determined to find an alternative solution, he discovered Sodium Dichloroacetate (DCA) and began self-treatment.

His daily regimen included:

  • 1,000 mg of Sodium Dichloroacetate,
  • 500 mg of Vitamin B1,
  • 600 mg of Alpha-Lipoic acid,
  • 500 mg of Green tea leaf extract (Jarrow brand),
  • 10 oz. of Mountain Dew, mixed with DCA for consumption.
  • The results were astonishing:

Within two weeks, his fever, night sweats, fatigue, and weight loss began to improve.

  • After one month, his enlarged lymph nodes started to shrink, becoming non-palpable after two months.
  • By day 71, his symptoms had completely vanished. He regained his energy, appetite, and sleep quality.
  • In an extraordinary turn of events, a PET scan in December 2008 (four months after starting DCA therapy) revealed no trace of cancer. He had effectively overcome Non-Hodgkin lymphoma.

At his last check-up, now aged 52, he reported feeling well and continuing a maintenance dose of DCA three times a week, along with Thiamine and Alpha-Lipoic acid. He enjoys a full, active life and works full-time. The most recent PET scan showed no signs of cancer, and aside from slightly elevated triglyceride and cholesterol levels, his blood tests are normal. This remarkable recovery highlights the potential of alternative treatments in certain cancer cases.

Beyond just Fenbendazole, those exploring this alternative treatment often combine it with other substances like DCA, 2DG etc. These combinations seem to enhance the overall effect, increasing Fenbendazole’s ability to combat cancer.

Leave a Reply